

October 15, 2008 DURB Meeting Summary

Issue	Attachment*	Action	Notes
Roll Call			<p>Present: Dr. Swee, Dr. Marcus, Dr. Moynihan, Dr. Condoluci, Mr. Schafer, Dr. Moore, Ms. Olson, Dr. Gochfeld, Ms. Martinez-Rodriguez, Dr. Barberio, Dr. Goen, Dr. Zanna</p> <p>Absent: Dr. Woodward, Dr. Lichtbroun</p>
Review of Minutes	Pages 3-4; Tab 1	Approved	Minutes from June 18, 2008 meeting were approved
Secretary's Report	Page 5; Tab 2		<p>The State will address follow-up items from the June 2008 meeting such as drafting the dental prophylaxis newsletter. The DURB also requested the State to follow-up on its recommendation to send a letter to the HMOs regarding the use of Lyrica® for HIV neuropathy. The NJDURB annual report will be worked on for state fiscal year '08 and upon completion will be distributed to DMAHS staff and the Board. For clarification it was noted that only atypical anti-psychotics and certain medications used for the treatment of substance abuse are carved out services from the NJ Managed Care Organization Contract.</p>
Business			
A. Antibiotic Duration of therapy	Pages 7-8; Tab 3		<p>Unisys presented a report highlighting the use of antibiotics greater than 21 days. Four widely prescribed antibiotics were reviewed: levofloxacin, clarithromycin, amoxicillin, and amoxicillin/clavulanate. Diagnoses of osteomyelitis, opportunistic infections' prophylaxis, MRSA-related infections, and Lyme Disease were excluded from the analysis. The average days of treatment for levofloxacin, clarithromycin, and amoxicillin and amoxicillin/clavulanate were 43, 40, and 35 days, respectively. Unisys reviewed 100/2,148; 70/70; and 100/5,177 patients for levofloxacin, clarithromycin, and amoxicillin and amoxicillin/clavulanate respectively. The Board requested that Unisys reach out to the prescribers and obtain</p>

October 15, 2008 DURB Meeting Summary

Issue	Attachment*	Action	Notes
			diagnoses for extended duration of use on the patients reviewed.
B. HIV Report and Newsletter	Pages 9-15; Tab 4		The Board approved the proposed HIV Opportunistic Infections newsletter.
C. Long Acting Beta Agonist Newsletter	Pages 15-18; Tab 5		Suggestions were made to improve the LABA newsletter by making the black box warning more prominent, utilizing current NIH guidelines, delete background information, and highlight the drug utilization review issue of duplication with these agents. The updated newsletter will be presented again at the next meeting.
D. Suboxone® Newsletter	Pages 19-22; Tab 6		The Board recommended that the newsletter be a one page announcement that will refer a reader to more information on Suboxone® on the DURB website. A final version of the announcement and newsletter will be sent to the DURB members for their comments.
Informational Highlights			
1. Unisys Reports	Pages 23-26; Tab 7		Unisys will attempt to breakdown the "directed intervention" category for more detailed information on reason for denials.
2. Most Frequently Utilized Drugs	Pages 17-58; Tab 8		The State will combine specific therapeutic classes. This will allow for an accurate reflection of expenditures.
3. Proposed Meeting Dates	Page 59; Tab 9		The proposed meeting dates: January 21, 2009, April 15, 2009, June 24, 2009, and October 21, 2009 were approved by the Board.
Follow-up Items			
Lyrica® letter to HMOs			The State will discuss the use of Lyrica® for indications beyond those approved by the FDA with the HMOs.
Newsletter on Dental Prophylaxis			The State will draft a newsletter addressing recent updates to the guidelines.
DURB SFY 2008 annual report			The DURB annual report is currently being worked on for SFY 2008. Upon completion it will be circulated to DMAHS and the Board for approval.

October 15, 2008 DURB Meeting Summary

Issue	Attachment*	Action	Notes
HMO Denial Reporting			The State requested that the Managed Care Organizations provide a format for quarterly denials that is similar to the Unisys report. These will be presented when the reports are in for the Board's information.